8 completed, 1 unknown, 1 withdrawn. 1 Early Phase 1, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 3 | 1 | Unknown 1 |
| Phase 4 | 1 | Completed 1 |
Follow Hyperlipidemia, Familial Combined: new trials by email Literature Review of Hyperlipidemia, Familial Combined trials Research Report on Hyperlipidemia, Familial Combined
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry PCSK9 Inhibitor [EPC], Standard lipid lowering therapy - Dyslipoproteinemias, Hypercholesterolemia, Familial | Completed | GWT-TUD GmbH | 1695 | 2017-05-18 | 2025-05-09 | |
| Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia Atorvastatin 20mg, Omega-3-acids ethylesters 90 4g, Placebo(Omega-3-acids ethylesters 90) - Hyperlipidemia, Familial Combined | Phase 3 | Unknown | Kuhnil Pharmaceutical Co., Ltd. | 80 | 2014-01-01 | 2014-03-20 |
| Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes OGTT - Atherosclerosis, Leukocyte Activation Disorder | Not applicable | Completed | Sint Franciscus Gasthuis | 51 | 2007-06-01 | 2014-05-05 |
| Understanding the Genetic Basis of Familial Combined Hyperlipidemia in Mexican Individuals Hyperlipidemia, Familial Combined, Coronary Disease | Completed | University of California, Los Angeles | 998 | 2006-07-01 | 2012-01-12 | |
| Evaluation of Non-invasive Measurements of Atherosclerosis in Cardiovascular Risk Stratification Cardiovascular Disease | Completed | Radboud University Medical Center | 1960 | 2005-05-01 | 2012-03-15 | |
| Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism chenodeoxycholic acid, placebo capsules - Metabolic Syndrome, Familial Hypertriglyceridemia | Early Phase 1 | Completed | University Hospital, Basel, Switzerland | 30 | 2004-10-01 | 2012-03-09 |
| Genomic Dissection of a QTL Affecting the Lipid Profile Cardiovascular Diseases, Heart Diseases | Withdrawn | Medical College of Wisconsin | 2003-07-01 | 2015-09-10 | ||
| Study to Compare Welchol and TriCor to TriCor Alone in Patients With High Cholesterol colesevelam HCl tablets and fenofibrate tablets, fenofibrate tablets and Welchol placebo tablets - Hypercholesterolemia, Hyperlipidemia, Familial Combined | Phase 4 | Completed | Daiichi Sankyo | 129 | 2003-02-01 | 2015-04-03 |
| Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia Atherosclerosis, Cardiovascular Diseases | Completed | University of Washington | 450 | 2001-04-01 | 2014-12-11 | |
| Genetic Epidemiology of Hypertriglyceridemia Cardiovascular Diseases, Coronary Disease | Completed | University of Washington | 1993-07-01 | 2016-02-10 |
Cardiovascular Diseases (4) · Atherosclerosis (2) · Coronary Disease (2) · Heart Diseases (2) · Hypercholesterolemia (2) · Hyperlipoproteinemia Type II (2) · Hyperlipoproteinemia Type IV (2) · Diabetes Mellitus, Type 2 (1) · Dyslipidemias (1) · Homozygous Familial Hypercholesterolemia (1) · Metabolic Syndrome (1) · Obesity (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (10) · Genetic Diseases, Inborn (10) · Hyperlipidemias (10) · Lipid Metabolism Disorders (10) · Lipid Metabolism, Inborn Errors (10) · Metabolic Diseases (10) · Metabolism, Inborn Errors (10) · Nutritional and Metabolic Diseases (10) · Dyslipidemias (9) · Hyperlipoproteinemias (4) · Vascular Diseases (4) · Arterial Occlusive Diseases (2) · Arteriosclerosis (2) · Cardiovascular Diseases (2) · Glucose Metabolism Disorders (2)
Colesevelam Hydrochloride (2) · Atorvastatin (1) · Chenodeoxycholic Acid (1) · Ezetimibe (1) · Fatty Acids, Omega-3 (1) · Fenofibrate (1) · Fibric Acids (1) · Glucose Tolerance Test (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Niacin (1) · alirocumab (1) · erucylphosphocholine (1) · evolocumab (1)
University of Washington (2) · Daiichi Sankyo (1) · GWT-TUD GmbH (1) · Kuhnil Pharmaceutical Co., Ltd. (1) · Medical College of Wisconsin (1) · Radboud University Medical Center (1) · Sint Franciscus Gasthuis (1) · University Hospital, Basel, Switzerland (1) · University of California, Los Angeles (1)
Germany (1) · Mexico (1) · Netherlands (1) · South Korea (1) · Switzerland (1) · United States (1)
Andreas Birkenfeld, MD, PhD (1) · Anton FH Stalenhoef, MD, PhD (1) · Bernd Hohenstein, MD, PhD (1) · David Pittrow, MD, PhD (1) · Elisabeth Steinhagen-Thiessen, MD, PhD (1) · Hee Kyoung Cheon, Ph.D. (1) · Hong Seog Seo, Ph.D. (1) · Jacqueline de Graaf, MD, PhD (1) · John Brunzell (1) · Klaus G Parhofer, MD, PhD (1) · Manuel Castro Cabezas, MD, PhD (1) · Martin den Heijer, MD, PhD (1) · Melissa Austin (1) · Mi-Seung Shin, Ph.D (1) · Paivi E. Pajukanta, MD, PhD (1)
PMID 15636580, PMID 16128862, PMID 16197666, PMID 16677651, PMID 17157483, PMID 17227806, PMID 17324737, PMID 17419684, PMID 17461984, PMID 17953518, PMID 18096166, PMID 18762168, PMID 19417041, PMID 19453648, PMID 20210840, PMID 21091808, PMID 21128932, PMID 21144110, PMID 21209464, PMID 21226677, PMID 22199011, PMID 25456098, PMID 36178485, PMID 40270128, PMID 40760109
P01HL030086 (1), R01HL049513 (1), R01HL074168 (1), R01HL082762 (1)